NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

內分泌治療藥的全球市場:2021年∼2025年

Global Endocrinology Drugs Market 2021-2025

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 1017101
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
內分泌治療藥的全球市場:2021年∼2025年 Global Endocrinology Drugs Market 2021-2025
出版日期: 2021年05月26日內容資訊: 英文 120 Pages
簡介

全球內分泌治療藥的市場規模在2021年∼2025年間,預測將成長到252億5000萬美元,在預測期間中預計將以6%的年複合成長率增長。

該市場成長的主要因素有內分泌疾病發病率增加,內分泌疾病是內分泌學的一個有前途的管道。

本報告涵括內分泌治療藥的全球市場的整體分析,提供市場規模與預測,趨勢,成長要素,課題,及約25供應商的分析。

目錄

  • 摘要整理
    • 市場概要
  • 市場形勢
    • 市場生態系統
    • 價值鏈分析
  • 市場規模
    • 市場定義
    • 市場區隔分析
    • 2020年的市場規模
    • 市場預測:從2020年∼2025年的預測
  • 波特的五力分析
    • 五力彙整
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭的威脅
    • 市場情況
  • 市場區隔:各治療領域
    • 市場區隔
    • 各治療領域比較
    • 糖尿病治療藥:市場規模與預測(2020年∼2025年)
    • hGH:市場規模與預測(2020年∼2025年)
    • 甲狀腺荷爾蒙障礙:市場規模與預測(2020年∼2025年)
    • 其他:市場規模與預測(2020年∼2025年)
    • 各治療領域的市場機會
  • 客戶形勢
    • 客戶形勢
  • 各地區形勢
    • 各地區市場區隔
    • 各地區比較
    • 北美:市場規模與預測(2020年∼2025年)
    • 歐洲:市場規模與預測(2020年∼2025年)
    • 亞洲:市場規模與預測(2020年∼2025年)
    • 其他地區:市場規模與預測(2020年∼2025年)
    • 主要國家
    • 地區的市場機會
    • 市場推動因素
    • 市場課題
    • 市場趨勢
  • 業者情勢
    • 業者情勢
    • 創造性破壞狀況
    • 競爭模式
  • 供應商分析
    • 交易廠商
    • 供應商的市場定位
    • Acerus Pharmaceuticals Corp.
    • Beta Cell NV
    • Eli Lilly and Co.
    • GlaxoSmithKline Plc
    • Ipsen Pharma SA
    • Merck and Co. Inc.
    • Novartis AG
    • Novo Nordisk AS
    • Pfizer Inc.
    • Sanofi SA
  • 附錄
    • 調查範圍
    • US$的匯率
    • 調查手法
    • 簡稱的清單
目錄
Product Code: IRTNTR40785

Technavio has been monitoring the endocrinology drugs market and it is poised to grow by $ 25.25 bn during 2021-2025, progressing at a CAGR of over 6% during the forecast period. Our report on endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the incidence of endocrine disorders and promising pipeline for endocrinology. In addition, an increase in the incidence of endocrine disorders is anticipated to boost the growth of the market as well.

The endocrinology drugs market analysis includes therapy area segment and geographic landscape.

Technavio's endocrinology drugs market is segmented as below:

By Therapy Area

  • Diabetes drugs
  • hGH
  • Thyroid hormone disorders
  • Others

By Geography

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the research in novel dosage formulations and drug delivery systems as one of the prime reasons driving the endocrinology drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on endocrinology drugs market covers the following areas:

  • Endocrinology drugs market sizing
  • Endocrinology drugs market forecast
  • Endocrinology drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endocrinology drugs market vendors that include Acerus Pharmaceuticals Corp., Beta Cell NV, Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma SA, Merck and Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., and Sanofi SA. Also, the endocrinology drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five forces summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Therapy area
    • Market segments
    • Comparison by Therapy area
    • Diabates drugs - Market size and forecast 2020-2025
    • hGH - Market size and forecast 2020-2025
    • Thyroid hormone disorders - Market size and forecast 2020-2025
    • Others - Market size and forecast 2020-2025
    • Market opportunity by Therapy area
  • Customer landscape
    • Customer landscape
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Asia - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Vendor landscape
    • Landscape disruption
    • Competitive Scenario
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Acerus Pharmaceuticals Corp.
    • Beta Cell NV
    • Eli Lilly and Co.
    • GlaxoSmithKline Plc
    • Ipsen Pharma SA
    • Merck and Co. Inc.
    • Novartis AG
    • Novo Nordisk AS
    • Pfizer Inc.
    • Sanofi SA
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

Exhibits

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Other1 - Market share 2020-2025 (%)
  • 22: Comparison by Other1
  • 23: Diabates drugs - Market size and forecast 2020-2025 ($ million)
  • 24: Diabates drugs - Year-over-year growth 2020-2025 (%)
  • 25: hGH - Market size and forecast 2020-2025 ($ million)
  • 26: hGH - Year-over-year growth 2020-2025 (%)
  • 27: Thyroid hormone disorders - Market size and forecast 2020-2025 ($ million)
  • 28: Thyroid hormone disorders - Year-over-year growth 2020-2025 (%)
  • 29: Others - Market size and forecast 2020-2025 ($ million)
  • 30: Others - Year-over-year growth 2020-2025 (%)
  • 31: Market opportunity by Other1
  • 32: Customer landscape
  • 33: Market share by geography 2020-2025 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2020-2025 ($ million)
  • 36: North America - Year-over-year growth 2020-2025 (%)
  • 37: Europe - Market size and forecast 2020-2025 ($ million)
  • 38: Europe - Year-over-year growth 2020-2025 (%)
  • 39: Asia - Market size and forecast 2020-2025 ($ million)
  • 40: Asia - Year-over-year growth 2020-2025 (%)
  • 41: ROW - Market size and forecast 2020-2025 ($ million)
  • 42: ROW - Year-over-year growth 2020-2025 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: Acerus Pharmaceuticals Corp. - Overview
  • 52: Acerus Pharmaceuticals Corp. - Business segments
  • 53: Acerus Pharmaceuticals Corp. - Key offerings
  • 54: Acerus Pharmaceuticals Corp. - Key customers
  • 55: Acerus Pharmaceuticals Corp. - Segment focus
  • 56: Beta Cell NV - Overview
  • 57: Beta Cell NV - Product and service
  • 58: Beta Cell NV - Key offerings
  • 59: Beta Cell NV - Key customers
  • 60: Beta Cell NV - Segment focus
  • 61: Eli Lilly and Co. - Overview
  • 62: Eli Lilly and Co. - Business segments
  • 63: Eli Lilly and Co. - Key offerings
  • 64: Eli Lilly and Co. - Key customers
  • 65: Eli Lilly and Co. - Segment focus
  • 66: GlaxoSmithKline Plc - Overview
  • 67: GlaxoSmithKline Plc - Business segments
  • 68: GlaxoSmithKline Plc - Key offerings
  • 69: GlaxoSmithKline Plc - Key customers
  • 70: GlaxoSmithKline Plc - Segment focus
  • 71: Ipsen Pharma SA - Overview
  • 72: Ipsen Pharma SA - Business segments
  • 73: Ipsen Pharma SA - Key offerings
  • 74: Ipsen Pharma SA - Key customers
  • 75: Ipsen Pharma SA - Segment focus
  • 76: Merck and Co. Inc. - Overview
  • 77: Merck and Co. Inc. - Business segments
  • 78: Merck and Co. Inc. - Key offerings
  • 79: Merck and Co. Inc. - Key customers
  • 80: Merck and Co. Inc. - Segment focus
  • 81: Novartis AG - Overview
  • 82: Novartis AG - Business segments
  • 83: Novartis AG - Key offerings
  • 84: Novartis AG - Key customers
  • 85: Novartis AG - Segment focus
  • 86: Novo Nordisk AS - Overview
  • 87: Novo Nordisk AS - Business segments
  • 88: Novo Nordisk AS - Key offerings
  • 89: Novo Nordisk AS - Key customers
  • 90: Novo Nordisk AS - Segment focus
  • 91: Pfizer Inc. - Overview
  • 92: Pfizer Inc. - Business segments
  • 93: Pfizer Inc. - Key offerings
  • 94: Pfizer Inc. - Key customers
  • 95: Pfizer Inc. - Segment focus
  • 96: Sanofi SA - Overview
  • 97: Sanofi SA - Business segments
  • 98: Sanofi SA - Key offerings
  • 99: Sanofi SA - Key customers
  • 100: Sanofi SA - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations